Bristol-Myers Squibb Company hits a 52-week high as Breyanzi sales surge and AI imaging expands. Click for this updated look at BMY stock prospects.
Recent regulatory actions from the FDA, including new drug application (NDA) acceptances and labeling updates, introduce new clinical considerations for oncology nurses and advanced practice providers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results